Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer.

Clin Cancer Res · 2026 · PMC13266338 · PMID 41910595

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients with c-Met expression above the median showed a trend toward better clinical outcomes Acknowledgments AbbVie and the authors thank the participants, study sites, and investigators who participated in this clinical trial.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.